Word: normalization
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
Essentially, the new FDA-process fast track offers conditional approval for appropriate drugs based on clinical trials that are smaller and faster than normal. The agency also allows "rolling submissions," meaning it will accept and release initial reviews of drug components that are prepared earlier than the rest. For Agouron the difference was startling: the FDA's review of the Viracept application took a total of only 83 days; in 1992 the average length of time for FDA drug approval was 19 months...
...waiting patients but also the firm's bottom line. Agouron spent the past 12 years pumping all its income--$56 million last year--into research on the technology and procedures later used to bring Viracept to market. Agouron's net loss last year was $19.5 million, and under normal FDA review, Viracept would still not have been able to earn money for several more years. Under the new rules, however, Agouron can profit immediately from sales of Viracept, which, as one of only four protease inhibitors currently revolutionizing AIDS treatments, is sure to sell well. Viracept could earn $500 million...
...always with the smaller schools, even normal interactions can take a bizarre twist...
Much effort has been made over the past four years in this paper to dissect the problem of Harvard's lack of so-called "normal" attendance figures. But perhaps another number should be listed when the attendance is cited--the number of campus reporters present...
...situation became so dire that Professor of Classics and History Christopher P. Jones felt obliged to interrupt the normal repose of a November Faculty meeting to protest the problems...